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years to provide vascular access for patients undergoing
hemodialysis. More than 1.5 million patients worldwide
have end stage renal disease and this population will
continue to grow. The arteriovenous ﬁstula is the preferred
vascular access for patients, but its patency rate at 1 year is
only 60%. The majority of arteriovenous ﬁstulas fail
because of intimal hyperplasia. In recent years, there have
been many studies investigating the molecular
mechanisms responsible for intimal hyperplasia and
subsequent thrombosis. These studies have identiﬁed
common pathways including inﬂammation, uremia,
hypoxia, sheer stress, and increased thrombogenicity.
These cellular mechanisms lead to increased proliferation,
migration, and eventually stenosis. These pathways work
synergistically through shared molecular messengers. In
this review, we will examine the literature concerning the
molecular basis of hemodialysis vascular access
malfunction.
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Kidney International (2016) 89, 303–316A rteriovenous ﬁstulas (AVFs) and grafts were intro-duced over 50 years ago and have been used exten-sively to provide vascular access for patients requiring
hemodialysis (HD).1,2 AVFs have lower rates of infection and
complications in comparison to other modes of HD access
and are the preferred method of vascular access in dialysis
patients.1 The Fistula First Initiative has helped make AVFs
the preferred method of HD vascular access.3 As a result,
there has been an increase in the number of patients in whom
AVFs are placed worldwide, including Europe and Japan.4,5
AVFs have also been recommended in the pediatric popula-
tion.6 In the United States alone, there are nearly 600,000
patients with end-stage renal disease (ESRD) and approxi-
mately 400,000 on HD.7 These numbers are expected to grow
in the coming years. Given the magnitude of renal disease,
AVFs will continue to be an effective and necessary tool in the
coming years.
Although AVFs have proven to be an essential tool, they are
by no means without problems. One of the major weaknesses
of AVFs is the time it takes for the ﬁstula to mature. This time
can be further worsened due to lack of patient education,
predialysis planning, and follow-up care. As a result, many
patients may need to use tunneled dialysis catheters, which
are less favorable due to their associations with bacteremia,
resulting in increased morbidity, mortality, and cost.5,8,9
Unfortunately, only 60% of AVFs will be functional at
12 months.10–12 Several studies have shown that patency rates
are linked to many variables, ranging from age, presence of
diabetes, body mass index, smoking, cytomegalovirus infec-
tion, total plasma cholesterol, protein intake, peripheral
vascular disease, vessel characteristics, mean arterial pressure,
surgical technique, and the use of vascular staples, along with
many others.13–17 Despite the heterogeneity of the factors
associated with AVF patency, it is suspected that many of them
act through pathologically similar molecular mechanisms.
The histology of intimal hyperplasia (IH) is characterized by
an abundance of contractile smooth muscle cells, myoﬁbro-
blasts, ﬁbroblasts, and macrophages, which eventually narrow
the venous outﬂow leading to stenosis and a reduction in blood
ﬂow or in many cases thrombosis (Figure 1). There are many
studies that have demonstrated that IH occurs because of
several vascular biology pathways, including inﬂammation,
uremia, hypoxia, shear-stress, and thrombosis.2,18–22 These
mechanisms are thought to work in concert through linked303
Figure 1 | (a, b) Fistulograms showing a stenosis at the polytetraﬂuoroethylene graft anastomosis to the basilic vein. (c) A gross
specimen from a different patient showing thickening of the vein to graft anastomosis. Hematoxylin and eosin stain (d) at 10 magniﬁcation
demonstrating a thickened neointima and (e) at 40 magniﬁcation (red box in d) showing increased cellular proliferation. ePTFE, expanded
polytetraﬂuoro-ethylene.
r ev i ew A Brahmbhatt et al.: Molecular mechanismscytokine cascades and possibly epigenetic changes that induce
negative remodeling to occur, leading to ﬁstula failure
(Figure 2).23 This review will focus on the events triggered by
renal failure as well as vascular access (VA) surgery that
frequently lead to AVF failure. Because hemodynamic forces
play an important role in vascular tone regulation and
inﬂammation, we will review speciﬁcally the relation between
vascular vessel wall stresses and themolecularmechanisms thatFigure 2 | Schematic of vascular injuries contributing to stenosis
formation in hemodialysis vascular access. IH, intimal hyperplasia.
304are responsible for vessel wall changes and ultimately for AVF
dysfunction.23
Animal models
Given the complex nature of AVF failure in the setting of
chronic kidney disease (CKD), several animal models have
been established to study this phenomenon. There are many
in vitro models utilizing cell culture. Whereas these models
are useful for studying isolated phenomenon, they fail to
capture all of the factors at play in AVF failure. Initial work in
AVF and arteriovenous graft failure utilized carotid artery to
jugular vein and also femoral artery to femoral ﬁstulas and
grafts. This was performed in pigs, rats, and mice. All of them
showed signiﬁcant IH at varying time points.24–27 However,
these did not account for the systemic effects of CKD that
play a signiﬁcant role in AVF failure.28 In order to capture
these systemic effects, models with induced kidney failure
were developed. These models induced CKD in the animals
via complete and/or partial nephrectomy. One kidney would
be removed or embolized and/or the upper pole of the
remnant kidney would also be ligated or embolized. These
one-half or ﬁve-sixths nephrectomy models allowed for
progression of CKD. Blood urea nitrogen was noted to be
elevated for up to 8 weeks after nephrectomy. In the porcineKidney International (2016) 89, 303–316
Figure 4 | iNOS and Arg-1 expression using qRT-PCR. Inducible
nitric oxide synthase (iNOS) and arginase-1 (Arg-1) expression
using quantitative reverse transcriptase polymerase chain reaction
(qRT-PCR) in graft veins and control veins at 3 and 7 days after
arteriovenous ﬁstula placement in mice with established chronic
kidney disease. There is a signiﬁcant increase in the mean Arg-1
expression with a decrease in iNOS between day 3 and 7. Each bar
shows the mean  SEM of 3 samples per group. Two-way analysis
of variance with Student t test with post hoc Bonferroni correction
was performed. P < 0.05.
A Brahmbhatt et al.: Molecular mechanisms r ev i ewmodel, stable CKD lasts from 4 to 12 weeks after nephrec-
tomy.29–32 In the murine model, 4 weeks after nephrectomy,
the mice underwent placement of an AVF.33 These models
provide researchers with comprehensive paradigms to study
AVF failure and apply translatable therapies. There are some
limitations as there are differences in surgical technique, ﬁs-
tula sites, grafts, effects of HD, repeat cannulation, and ability
to undergo angioplasty.33–35 Some of these considerations can
be addressed depending on the model used. However, there
have been many histological comparisons made among hu-
man, porcine, rat, and murine models. These ﬁndings show
similar cellular phenotypes and staining patterns, and they
suggest equivalent molecular mechanisms across all models of
AVF failure.20,36,37
Inﬂammation
Inﬂammation in the setting of AVF can be divided into 2
parts. First, there is local inﬂammation caused by the trauma
of ﬁstula creation and local hypoxia. Second, there is a sys-
temic rise in inﬂammation, which occurs because of uremia
that is present in CKD patients. The local inﬂammatory
response is characterized by the presence of macrophages
(CD68) and inﬁltrating lymphocytes (CD3). This inﬁltration
is more signiﬁcant in the setting of CKD.38 CD68- and CD3-
positive cells have been found in increased numbers in ste-
notic vessels. It is hypothesized that this local inﬂammatory
response is caused by the release of macrophage migration
inhibitory factor.39,40 Macrophage migration inhibitory factor
has been shown to potentiate neointimal thickening by
driving inﬂammatory cells toward the neointima and leading
to the proliferation of medial and intimal cells. It has been
identiﬁed in clinical and experimental models of HD vascular
access.41,42 Macrophage migration inhibitory factor actsFigure 3 | TNF-a, MCP-1, and IL-1b expression by qRT-PCR. Tissue
necrosis factor-alpha (TNF-a), monocyte chemoattractant protein-1
(MCP-1), and interlukin-1 beta (IL-1b) expression by quantitative
reverse transcriptase polymerase chain reaction (qRT-PCR) in graft
veins and control veins at 3 and 7 days after arteriovenous ﬁstula
placement in mice with established chronic kidney disease. There is a
signiﬁcant increase in the mean TNF-a, MCP-1, and IL-1b expression
at 3 days in graft veins when compared with control veins (P < 0.05).
Each bar shows the mean  SEM of 3 samples per group. Two-way
analysis of variance with Student t test with post hoc Bonferroni
correction was performed. *P < 0.05.
Kidney International (2016) 89, 303–316through the CD74 receptor, chemokine (C-X-C motif) re-
ceptor 2, and chemokine (C-X-C motif) receptor 4.40 These
in turn act through extracellular signal-regulated and p38
mitogen-activated protein kinase pathways that up-regulates
vascular endothelial growth factor (VEGF)-A, interleukin
(IL)-8, and monocyte chemotactic protein 1 (MCP-1)
(Figure 3). Experimental data using a MCP-1 knockout
mouse model show that there is a reduction in IH.43 More-
over, in the murine model of CKD with AVF, there is an
increase in gene expression of arginase-1, a marker for
proinﬂammatory macrophages, followed by an increase in
inducible nitric oxide, a marker for reparative macrophages in
outﬂow vein samples removed from experimental murine
model of AVF with CKD (Figure 4).
VEGFs have many subtypes that exhibit differential effects
that will be discussed later, but in the context of inﬂamma-
tion, they serve as leukocyte chemo attractants, which
potentiate local inﬂammation.44 IL-8 recruits monocytes and
neutrophils by acting through chemokine (C-X-C motif)
receptors 1 and 2. MCP-1 induces activation and migration of
monocytes, memory T lymphocytes, and natural killer cells.45
Of these 3 cellular types, monocytes are likely the most
contributory to inducing AVF failure. Experimental data from
our laboratory demonstrate that decreasing monocytes and
macrophages using clodronate results in a reduction in F4/80
(þ) macrophages, reduction in lymphocyte antigen 6 com-
plex (Ly-6C) Hi (þ) monocytes, and an increase in Ly-6C Lo
(þ) monocytes with subsequent reduction in IH (Figures 5
and 6). Ly-6C Hi (þ) monocytes contribute to pro-
inﬂammatory macrophages and Ly-6C Lo (þ) monocytes
contribute to reparative macrophages.43,46–48 The increase in
Ly-6C Lo (þ) with a reduction in Ly-6C Hi (þ) cells is305
Figure 5 | Flow cytometry for bone marrow Ly-6C Hi and Ly-6C Lo cells and splenic F4/80(D) cells from animals treated with CLO and
PBS at day 14. (a) Representative ﬂow diagram from a clodronate (CLO)-treated animal. (b) Representative ﬂow diagram from a control–
phosphate-buffered saline (PBS)-treated–animal. (c) Pooled data from 2 PBS-treated animals and 3 CLO-treated animals at day 14. Each bar
shows the mean  SEM of 2 to 3 samples per group. Two-way analysis of variance with Student t test with post hoc Bonferroni correction was
performed. *P < 0.05.
r ev i ew A Brahmbhatt et al.: Molecular mechanismshypothesized to contribute to the reduction in IH, which is
consistent with other vascular injuries.43
Monocyte inﬁltration into the AVF is suspected to cause an
up-regulation of transforming growth factor beta 1 (TGF-b1)
and insulin-like growth factor 1. Both of these cytokines are
proatherogenic acting through vascular smooth muscle cells.
TGF-b1, despite being classically anti-inﬂammatory, has been
shown to lead to extracellular matrix (ECM) deposition,
causing thrombosis.21 Differences in TGF-b1 polymorphisms,
result in differing levels of TGF-b1 production, have also been
correlated with rates of AVF patency.49
TGF-b1 and its family of receptors have been implicated in
many different cellular changes. Recent work has shown that
by blocking the downstream core fucosylation of TGF b, one
can reduce markers of renal ﬁbrosis.50 Although theFigure 6 | H&E staining of outﬂow veins removed from animals
treated with PBS and CLO at day 14. Hematoxylin and eosin (H&E)
staining of outﬂow veins removed from PBS-treated and CLO-treated
animals at day 14 after arteriovenous ﬁstula placement. There is a
reduction in the neointima (n) of the CLO-treated animals when
compared with PBS control animals. Asterisk (*) shows the lumen
of the vessel. Scale bars ¼ 50 mM. CLO, clodronate; m þ a, media/
adventitia; PBS, phosphate-buffered saline.
306mechanisms of renal ﬁbrosis and AVF failure vary, there is a
great deal of overlap. Fucosyltransferases have also been
shown mainly in cancer research to affect metastasis and
cellular adhesion. In addition, changes in glycosylation have
been shown to affect cell proliferation, transformation,
migration, and apoptosis. Most of this work has taken place in
the context of cancer progression.51,52 Examination of these
pathways may provide us with a better understanding of HD
vascular access failure and thus provide us with targets and
therapies.
In addition to TGF-b1, another prominent inﬂammatory
cytokine of interest in IH is tumor necrosis factor alpha
(TNF-a). Although historically thought of as an innate
immune response mediator, TNF-a can be activated by
hypoxia, reactive oxygen species, and local inﬂammation
and through an autocrine pathway.11,14 TNF-a is a 17-kDa
protein that acts via a nuclear factor kappa B (NF-kB) of
activated B cells receptor pathway for advanced glycation
end products and TNF-receptor 1. TNF receptor 1 is the
most common receptor in non-lymphoid tissues. However,
the receptor pathway for advanced glycation end products
has been shown to be unregulated in diabetic models and is
likely the driving force for up-regulation of vascular cell
adhesion protein 1.53 In smooth muscle cells (SMCs) from
veins, TNF-a, induces IL-1b and prostaglandin E2 release.
SMCs and endothelial cells (ECs) can also release TNF-a.
These responses suggest that SMCs, in addition to ECs in the
vessel wall, may serve as local propagators of the immune
response.5 TNF-a stimulation of ﬁbroblasts has also been
shown to induce proliferation, and these effects are
augmented by insulin-like growth factors.54 Additionally,
polymorphisms in TNF-a especially a 308 G>A promoterKidney International (2016) 89, 303–316
A Brahmbhatt et al.: Molecular mechanisms r ev i ewchange have been linked to an increased risk of AVF
thrombosis.55
Although TNF-a has apoptotic properties, they are masked
by the antiapoptotic NF-kB pathway that it activates. Thus,
only when the NF-kB pathway and/or protein synthesis are
nonfunctional does TNF-a become apoptotic.56 This largely
explains why TNF-a appears to be proliferative in the setting
of IH. Although many cells experience cellular injury at the
time of AVF placement, it is not enough to compromise the
antiapoptotic effects of the NF-kB pathway. Thus, TNF-a in
the setting of IH contributes synergistically with the prolif-
erative effects of other cytokines released during AVF
placement.
Uremia
In addition to local mediators, AVF failure is complicated by
systemic changes associated with CKD.28,38,57,58 One of the
major effects of ESRD is uremia, which is associated with
increased oxidative stress that causes a characteristic change in
circulating proteins. This oxidative stress is further compli-
cated by dialysis, which causes activation of phagocytes,
release of oxygen radicals, peroxidation of lipids, and ulti-
mately depletion of a patient’s antioxidant protectants. Recent
work has shown that cytokines implicated in IH formation,
which include IL-6, TGF-b1, and TNF-a, are elevated in
uremia. Additionally, markers of oxidative damage and lipid
peroxidation, 8-hydroxy-20-deoxyguanosine and 4-hydroxy-
2-nonenal, respectively, have also been identiﬁed.18 These
stressors have been shown to increase the levels of potent
mitogens, which include platelet-derived growth factor
(PDGF), endothelin 1, and the proliferative stimulator
TGF-b, compounded by the local inﬂammation and hypoxia
that take place during AVF creation.59
Uremia has also been shown to affect cellular calcium
extrusion, induce ﬁbrosis, increase insulin resistance, and
raise calcium phosphate deposition in the vessel wall.60,61
These changes together have been shown to increase
vascular calciﬁcations, which have been linked to AVF fail-
ure.62–64 Patients with higher serum levels of C-reactive
protein and sclerostin, an osteocyte derivative up-regulated in
calciﬁed SMCs, have higher rates of independently predicted
AVF failure.65 Vascular calciﬁcations have been tied to
changes in mineral metabolism, parathyroid hormone, and
vitamin D, which in turn are modulated by systemic
inﬂammation. Several studies have shown the effects of
parathyroid hormone and vitamin D on vascular SMCs.
Although the true mechanism is unknown, it is likely that
vitamin D can have differential effects on vascular SMCs
depending on confounding cellular signals.36,66
In addition to their direct effects on vascular SMCs, these
factors also affect bone metabolism. CKD has been related to
abnormal bone pathology. It is unclear how and whether these
2 processes affect one another. Recent work has revealed
vitamin K, ﬁbroblast growth factor 23, bone morphogenetic
protein-2, osteocalcin, osteopontin, matrix gla, alkaline phos-
phatase, and others affect bone metabolism, renal activity, andKidney International (2016) 89, 303–316peripheral vasculature.57,67 These factors along with the re-
ceptor activator of NF-kB/receptor activator of NF-kB
ligand/osteoprotegerin triad may affect osteoclasts both in the
bone and in the vessel wall, leading to atherosclerosis. It is
likely that the uremia and increased reactive oxygen species in
CKD patients may exert differential effects on mesenchymal-
derived cells in both the arterial wall and bone.68,69 Studying
these mechanisms could provide a stronger basis for many
therapies such as phosphate binders, vitamin D, sodium
thiosulfate, speciﬁc receptor antibodies, and antioxidants.70–72
Hypoxia
Hypoxia is a potent inducer of many genes, which promote
angiogenesis and act in concert with inﬂammatory and shear
stress–mediated processes. In the setting of IH, hypoxia
deriving from damage to the vasa vasorum of the adventitia
layer of AVF primes the vessel for negative remodeling by
activating angiogenic and inﬂammatory genes. Hypoxia exerts
its effect on molecular signaling by activation of hypoxia-
inducible factors. Of this family of transcription factors,
hypoxia-inducible factor 1 a is the best studied and has been
found in increased levels in animal and human models of
IH.33,73 Hypoxia-inducible factor 1a and its downstream
mediators have also been seen in models of venous hyper-
tension. However, these latter models lack the surgical injury
of the vasa-vasorum thought to cause hypoxia in IH, sug-
gesting that other mechanisms may also be at work.33,74
Hypoxia-inducible factor 1a expression is thought to be
involved in a positive angiogenic feedback loop, inﬂuencing a
multitude of downstream molecular mechanisms, which re-
sults in angiogenesis, inﬂammation, cell proliferation, and
deposition of collagen.75 One of the most important down-
stream mediators is VEGF. The arterialization of the venous
vessel is likely mediated by VEGF-A. It is suspected that
overexpression of VEGF-A contributes to negative remodeling
and IH.76 A recent study from our laboratory77 demonstrated
that reducing VEGFA gene expression at the time of AVF
placement reduced IH formation. Polymorphisms in VEGF-A
speciﬁcally the VEGF-936C/C genotype were found to be 5.54
times more likely to develop and occlude AVF. The poly-
morphism also affects circulating levels, which were higher
than those with the VEGF-936 C/C polymorphism.78
VEGF acts on both receptors in its family VEGFR-1 and
VEGFR-2. VEGFR-1 acts in a positive manner through a
tyrosine kinase, promoting endothelial growth. VEGFR-1 is
also thought to activate macrophages, further increasing the
inﬂammatory setting of the AVF.79 VEGFR-2, also a tyrosine
kinase receptor, acts mainly through the phospholipase-cg
protein kinase-c pathway. VEGFR-2 is strongly expressed in
vasculature. It promotes EC proliferation and differentiation
into vascular cells.80,81 VEGFR-2 is hypothesized to increase
SMC proliferation via extracellular signal-regulated and Akt
signaling.76 Blockade of the Akt pathway has shown to
partially inhibit proliferation of venous SMCs.82 VEGF-A can
cause activation of matrix metalloproteinase (MMP)-9, which
causes remodeling of the basement membranes and ECM. In307
r ev i ew A Brahmbhatt et al.: Molecular mechanismsaddition to VEGF-A, hypoxia-inducible factor 1a also acti-
vates MMP-2, which degrades the ECM. ADAMTS-1 is
another matrix metalloproteinase that has also been increased
in experimental models of AVF and clinical samples and is
thought to have a similar role to MMP-2 and MMP-9.33 This
remodeling of the ECM works synergistically with the
proliferative effects of VEGFA, leading to IH.75 Reducing
ADAMTS1 expression using lentivirus short hairpin
RNA–mediated technology leads to positive vascular remod-
eling in experimental animal models.83
Recent work on VEGF has revealed many subtypes with
differing effects. Much of this work has taken place in cancer
models and has shown that VEGF isoforms can dictate
angiogenesis and in some cases can even be antiangiogenic.84
For example, VEGF-A165b is antiangiogenic and its splice
variant VEGF-A165a is notably proangiogenic in the setting
of peripheral artery disease.85 Work by Nowak et al.,86
demonstrated that proximal splice site variants generate
proangiogenic VEGF isoforms that are activated by TNF-a.
TGF-b1 in contrast leads to more distal splice site variants,
likely through p38 mitogen-activated phosphatase kinase-Clk/
sty kinases.86 In addition, previous work has shown that
VEGF and TGF-b1 likely inﬂuence each other via a decap-
entaplegic homolog 3 (SMAD family member 3) pathway.
Up-regulation of TGF-b/SMAD family member 3 has been
shown to decrease apoptosis and increase secretion of
VEGF-A in SMCs. However, this relationship is likely to vary
depending on the microenvironment given that both mole-
cules can be proangiogenic or antiangiogenic.87–89 Recent
work by Wan et al.,76 has shown that VEGF-121 and VEGF-
165 isoforms are expressed as both mRNA and proteins inFigure 7 | Inﬂammatory cytokines in A-treated versus control
animals. Inﬂammatory cytokines are elevated in Avastin (A)-treated
vessels when compared with control animals (IgG) at days 7 and 14
after arteriovenous ﬁstula placement. Vascular endothelial growth
factor-A (VEGF-A), MCP-1, TNF-a, and IL-1b expression by qRT-PCR in
graft veins and control veins at 7 and 14 days after arteriovenous
ﬁstula placement in mice with established chronic kidney disease.
Each bar shows the mean  SEM of 4 to 6 samples per group. Two-
way analysis of variance with Student t test with post hoc Bonferroni
correction was performed. *P < 0.05. IL-1b, interlukin-1 beta; MCP-1,
monocyte chemoattractant protein-1; qRT-PCR, reverse transcriptase
polymerase chain reaction; TNF-a, tissue necrosis factor-alpha.
308SMCs exposed to hypoxic conditions. Moreover, reduction
in IH using Avastin (Genentech, South San Francisco, CA)
experimentally results in an increase in gene expression of
TNF-a, IL-1b, and MCP-1 (Figure 7).
In addition to VEGF-A, another major peptide activated
by hypoxia is PDGF. PDGF acts on phosphorylated platelet-
derived growth factor b receptor to increase myoﬁbroblast
expression mediated through the Akt and extracellular signal-
regulated pathways.22 Several studies have demonstrated the
efﬁcacy of blocking many of these pathways through receptor
antagonists, gene knockouts, and environmental changes in
reducing IH.76,90
Hemodynamics
AVF stenosis occurs predominantly on the venous side of
the anastomotic region where ECs experience high, non-
physiological blood ﬂow gradients with ﬂow instability
(Figure 8).91,92 The hemodynamic changes following AVF
creation result in short-term and long-term vascular remod-
eling with an increase in vessel caliber and thickening of
venous wall (i.e., venous arterialization).93 The hemodynamic
features causing vascular wall remodeling are ﬂuid wall shear
stress (WSS, the frictional force exerted by blood ﬂow on
vessel wall luminal surface) and intramural tensile strain
caused by elevated blood pressure.94–97
After AVF creation, there are important increases in WSS
and tensile strain caused by increased blood ﬂow and pres-
sure, which result in arterial and venous remodeling. AVF
maturation induces an increase in vessel wall diameter that
reestablishes physiological stress levels within the maturation
period of 4 to 6 weeks.98 This vascular remodeling is called
outward remodeling and likely derives from the well-known
effect of laminar shear stress increase on ECs. We have pre-
viously shown that a mechanism of outward remodeling in-
creases vessel lumen after AVF surgery.99 The preoperative
peak value of shear stress predicted with a very good agree-
ment the dimensional and functional changes observed after
AVF maturation.100 However, whereas this phenomenon
occurs in the venous side of the AVF, near the anastomosis,
ECs are locally exposed to large and fast gradients of WSS in
space and time. This is accompanied with reverse blood ﬂow,
which can also develop with fast velocity ﬂuctuations
(Figure 8), as was recently shown.101 Computational studies
of hemodynamics in AVF reported complex ﬂow patterns in
areas that are more prone to development of IH, as the inner
side of the venous segment of AVF.91 ECs are essential regu-
lators of WSS-induced vessel remodeling.102–104 Numerous
studies have addressed the effects of normal and pathological
WSS on vascular biology and especially on the endothelium.
EC morphology, gene and protein expression, as well as
protein release are all strongly affected by different WSS
patterns.105,106
It has been demonstrated, both in vivo and in vitro, that
ECs exposed to unidirectional and relatively high WSS show
a quiescent phenotype induced by the sustained expression
of several molecules. One of the most important is theKidney International (2016) 89, 303–316
Figure 8 | Schematic representation of molecular mechanism of IH development in native AVF. Section of a side-to-end arteriovenous
ﬁstula (AVF). Laminar blood ﬂow coming from the proximal artery stimulates the endothelial cells (ECs) with unidirectional wall shear stress
(WSS) until the anastomosis level where the blood ﬂow splits in 2 directions. At the vein curvature, the blood ﬂow becomes unstable with
disturbed and oscillating WSS and reverse ﬂows at the inner curvature of the anastomosis. After the curvature, blood ﬂow oscillations decrease
and WSS returns to almost unidirectional. The different WSS patterns generated on the endothelium lead wall remodeling. At (a), the unidi-
rectional WSS maintains vessel patency while at (b) oscillating and reversing WSS impair ECs quiescence leading to intimal hyperplasia (IH).
ALK-5, activin receptor-like kinases 1/5; Ang-II, angiotensin II; ECM, extracellular matrix; ET-1, endothelin 1; GCX, glycocalyx; IL-8, interleukin 8;
KLF-2, Krüppel-like factor 2; MCP-1 monocytes chemoattractant protein 1; MFs, myoﬁbroblasts; MMP, metalloproteinase; NO, nitric oxide; SMCs,
smooth muscle cells; TGF-b, transforming growth factor b; VCAM, vascular cell adhesion protein; VE, vascular endothelial; VSMC, vascular
smooth muscle cells.
A Brahmbhatt et al.: Molecular mechanisms r ev i ewtranscription factor Krüppel-like factor 2.107 Krüppel-like
factor 2 induces several downstream events that cause ECs
to assume an antioxidant state with a reduced mitotic and
apoptotic rate.108 It induces also a down-regulation of
proinﬂammatory paracrine signals such as MCP-1 and
IL-8.109 The mechanotransduction of physiological patterns
of WSS has profound effects on EC morphology, causing cell
elongation, which aligns toward the blood ﬂow direction
because of a cytoskeletal rearrangement. In vitro, static EC
monolayers can develop dense actin peripheral bands with a
few randomly orientated f-actin ﬁbers crossing the cell body.
Physiological ﬂows induce the disassembly of actin peripheral
bands and the formation of long, parallel actin stress ﬁbers
aligned to ﬂow direction.110,111 WSS also induces adherens
junction stability and promotes glycocalyx formation.93,112,113
These phenomena regulate EC permeability of the endothe-
lium and seem to maintain a quiescent EC state.82,114 Finally,
unidirectional WSS can increase endothelial nitric oxide (NO)
release115 that modulates the activation of MMP-2 and
MMP-9. The MMP-induced degradation of elastin ﬁbers is
necessary in permanent vessel wall remodeling.111Kidney International (2016) 89, 303–316Reduced endothelial permeability and unidirectional
WSS downregulate the production of chemoattractant sig-
nals such as MCP-1 and IL-8 by ECs. WSS also serves to
abrogate inﬂammation caused by AVF placement. Along
with beneﬁcial effects in terms of reendothelialization and
inﬂammation, unidirectional/high WSS is also involved in
vessel outward remodeling. Studies performed both in vivo
and in vitro showed that hemodynamics inﬂuence
the balance between NO and reactive oxygen species pro-
duction. For example, unidirectional WSS promotes the
constitutive and the inducible forms of NO synthase, the
precursors of NO.
In contrast to unidirectional ﬂow, oscillating ﬂow adjacent
to the vessel wall can locally develop in AVFs (Figure 8). These
vacillating forces have been suggested to cause activation of a
series of pathways that induce IH.116–119 Oscillating WSS
directly affects EC gene expression causing an increase in the
autocrine EC proliferation pathway that ultimately leads to
up-regulation of mitogen-activated protein kinases, NF-kB
nuclear translocation,110,120 and a down-regulation of Krüp-
pel-like factor 2 expression.105 The overall effect is a paracrine309
r ev i ew A Brahmbhatt et al.: Molecular mechanismsproliferative (i.e., increased level of IL-8, MCP-1 production),
proinﬂammatory, prooxidant EC state and an impaired
vascular tone regulation due to the reduction of NO synthesis
and the increase of endothelin 1 and angiotensin-2
levels.105,117 EC structure and function are also deeply
affected by mechanotransduction of ﬂow oscillations. Oscil-
lating WSS affects adherens junction stability by inducing
altered endothelial permeability and preventing favorable
cytoskeletal rearrangement.93,121 Adherens junction instability
causes impairment of contact inhibition of EC proliferation
due the switch of Akt-induced EC survival signaling to the
extracellular signal-regulated /mitogen-activated protein
kinase proliferative pathway.99 Another important effect of
oscillating WSS is the alteration of EC surface glycocalyx. This
has a detrimental effect on EC permeability and function.113
In vitro knockout of Syndecan-1 and Glypican-1, two of the
core proteins of EC glycocalyx, abolishes WSS-induced
cytoskeletal remodeling and NO production, respectively.122
Oscillating WSS also causes an increase in surface adhesion
molecules (vascular cell adhesion protein 1), inducing an
increased EC surface reactivity to circulating molecules.106
Finally, oscillating WSS leads to an increase of cytokines as
TNF-a123 and interferon gamma124 that induce MMP-2 and
MMP-9 production and unbalance matrix deposition and
degradation, affecting vascular wall remodeling.125 Thus,
oscillating WSS that may develop in speciﬁc sites of AVF has
important effects on nuclear and protein EC regulation,
potentially related to formation of neointimal layer.119
Beyond NO and reactive oxygen species stimulation, a
recent investigation has shown that WSS-induced vessel
remodeling is related to heme oxygenase (HO) production.
Inducible (HO-1) and constitutive (HO-2) forms are
heme-degrading enzymes that have been related to AVF
patency and survival.126–129 HO acts as a vasorelaxant, anti-
oxidant, and anti-inﬂammatory agent by generating carbon
monoxide and biliverdin and releasing ferrous iron from
heme.130 It has been recently reported that HO-1 is produced
in varying responses to both high and lowWSS as the result of
different pathways and to different extents.131 High ﬂow-
induced HO-1 is generated downstream to NO and
mitochondria-derived hydrogen peroxide. Low ﬂow induces
lower levels of HO-1 that lead to macrophage inﬁltration and
superoxide production within the vessel wall. A recent study
performed in a carotid ligation mice model showed that
HO-1 induced by vascular damage, probably via NF-kB
activation, is vasoprotective, resulting in vasodilation.128 The
same study showed that HO-2 deﬁciency is related to an in-
crease in development of IH. These in vivo studies suggest a
fundamental role for HO enzymes in promoting outward
remodeling and preventing IH. However, to deﬁne the precise
and univocal relationship between WSS and HO induction in
AVF further studies are required.
Biology of AVF failure
All the mechanisms described importantly inﬂuence the
biology of vascular tissue responsible for AVF failure.310Histology of stenotic AVF tissues reveals that an aggressive IH
is composed mainly of smooth muscle alpha-actin-positive,
vimentin-positive, and desmin-negative myoﬁbroblasts
(MFs) that migrate towards the intima of the injured vessel.37
In this intimal layer, increased levels of endothelin 1, TGF-b,
MCP-1, IL-6, and PDGF that colocalize with markers of
oxidative stress are present.21,59,108,126
As mentioned previously, oscillating WSS in time and
direction in the venous side of AVF anastomosis affects
endothelium integrity; sustaining EC paracrine signaling
while it impairs direct NO-induced vasodilation and inhibi-
tion of SMC migration, leading to AVF stenosis.37,115 A recent
study showed the serum of patients with matured AVFs had
signiﬁcantly higher levels of matrix tissue inhibitor of met-
alloproteinase compared with the serum of those with ailed
accesses.132 This suggests an imbalance of MMP inhibition
after initial wound recovery activation, leading to sustained
ECM remodeling and cell migration.
The previously mentioned functional changes in vascular
cells within the neointimal layer are highly dependent on the
activation of TGF-b superfamily signaling.133-135 The effects
of TGF-b on EC depend on context. TGF-b can bind distinct
receptor complexes, in which the subunits forming the re-
ceptors determine signaling speciﬁcity. Depending on the
activin receptor-like type of the receptor, TGF-b signaling can
inhibit endothelial cell proliferation (activin receptor-like 5)
or elicit an opposite response (activin receptor-like 1).
The effect of ﬂuid WSS on TGF-b signaling in EC is a
matter of interest. Recent reports show that steady ﬂows
induce SMAD family member 7 up-regulation that causes
inhibition of TGF-b signaling in mouse embryo mesenchymal
progenitor cells while oscillating ﬂows induce phosphoryla-
tion of SMAD family members 1/5, which stimulates EC
migration and proliferation.136,137,139 Finally TGF-b binding
to activin receptor-like 5 is required for WSS-induced
expression of Krüppel-like factor 2 in embryonic EC.138
Finally, it has been very recently reported that WSS mod-
ules the endothelial-to-mesenchymal transition.139
TGF-b1 is the main activator of ﬁbroblast transition to the
MF phenotype. MFs are the main cellular component of AVF
stenosis. MFs directly produce ECM proteins and MMP,
participating in ECM deposition and degradation, which are
required for MF migration to intima, during vessel healing.
The fate of MFs at the end of the healing process may
determine positive or negative vessel remodeling.37 To end
physiological tissue repair, a massive MF apoptosis is induced
by reduced growth factors, NO generation, and intact
ECM.54,140 A sustained TGF-b expression, as well as the
persistence of ECM remodeling, abolishes MF disappearance
leading to IH development.141,142 Besides the intimal layer in
AVF, the adventitial layer is also importantly affected by wall
remodeling induced by AVF creation.99 Thus, the adventitia
may be the site of ﬁbrosis and of major vascular reactive
oxygen species production that directly inactivates NO,
causing impairment of vessel tone regulation.22,143 This evi-
dence suggests that the adventitial layer plays an importantKidney International (2016) 89, 303–316
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remodeling.
The surgical injury related to AVF creation itself may cause
EC denudation and exposure of collagen type I, leading to
platelet adhesion, PDGF release, and tissue factor activation.
In addition to activation of the coagulation cascade, the
inﬂammatory cascade may be activated, with up-regulation of
NF-kB and the related activation of mRNA transcription.
Thus, this injury may recruit leukocytes, induce EC release of
heparanases (with effect on EC proliferation), and extracel-
lular proteases (MMPs) that affect ECM remodeling and
vascular SMC migration.144 Despite the fact that vascular
injury induced by surgical procedure potentially causes acti-
vation of several pathways related to IH, the fact that vessel
stenosis and VA early failure develop only in a fraction of
surgical procedures suggests the coexistence of other factors
in the development of IH.
Thrombosis
Thrombosis occurs in the setting of AVF secondary to
inﬂammation, WSS, and disturbed ﬂow of AVFs, which can
initiate and work synergistically to enhance the thrombotic
cascade. It is hypothesized that uremia and endothelial
damage can up-regulate thrombotic antibodies, platelet fac-
tors, and EC receptors. This prothrombotic state is then
worsened by shear stress and the hemodynamic changes in an
AVF ultimately leading to thrombosis.145–152 Several studies
have found increased levels of inﬂammatory cytokines, high-
sensitivity C-reactive protein, D-dimer, soluble IL-2 receptor,
and IL-6, among others. In addition, CKD patients have
higher levels of von Willebrand factor and p selectin, both
proteins that can cause platelet activation. Thrombin-
antithrombin III has also been found to be elevated, and
although the difference in levels is signiﬁcant, its efﬁcacy is
questionable due to its lagging nature and lack of speciﬁcity,
along with D-dimer.150,153 This cascade is enhanced by
thromboxanes and factors released from the platelets them-
selves.154–156
In addition to these factors, rates of thrombosis are
increased by some underlying hypercoagulable states such as
G20210A, but not other blood groups.157–161 There is some
conﬂicting evidence regarding factor V Leiden, as one study
demonstrated an increased risk, but another found no dif-
ference after regression analysis.158,162 Given the importance
of factor V Leiden, it likely plays a signiﬁcant role in inducing
thrombosis. One study found the single-nucleotide poly-
morphism rs6019 in the factor V Leiden to be an independent
risk factor for AVF thrombosis. This polymorphism increases
the half-life of factor V Leiden, by increasing its resistance to
protein C.163
Serum low-density lipoprotein has been associated with
AVF thrombosis, but anticardiolipin antibodies, triglycerides,
total cholesterol, and high-density lipoprotein have not.164
This is despite the fact that these latter 4 factors have been
implicated in atherosclerotic vessel damage and that high ti-
ters of anticardiolipin antibodies have been found in ESRDKidney International (2016) 89, 303–316patients.159 The rs1466535 single-nucleotide polymorphism
in the low-density lipoprotein receptor–related protein 1 gene
has also been signiﬁcantly associated with AVF failure. Low-
density lipoprotein receptor–related protein 1 is hypothe-
sized to act on MMP-9 and controlled by a PDGF/Smad
signaling.162
Additionally, HD has been shown to increase several
thrombotic and inﬂammatory proteins, despite heparin ther-
apy. The study found signiﬁcant increases in p selectin,
CD40L, stimulated platelet ﬁbrinogen, Co TAT, D-dimer, von
Willebrand factor, and high-sensitivity C-reactive protein
after HD. This suggests that shifting levels of uremia even if
corrective may lead to hypercoagulability.153,165,166
High levels of antiphospholipid antibody IgA b-glycopro-
tein I antibodies have been associated with AVF and are
independent risk factors for CVD in ESRD patients. Anti-
phospholipid antibodies are more prevalent in patients with
ESRD, likely due to uremic changes and endothelial injury.
This hypercoagulable state, along with the up-regulation of
endothelial receptors, promotes AVF thrombosis.148,149 In
addition to ﬁnding IgA anti-b2GPI, a recent study also
identiﬁed the human platelet antigen 3aa genotype as an
independent risk factor for AVF failure. Human platelet an-
tigen 3aa maps to a portion of glycoprotein IIb, with no
known hemostatic function, but it has been associated with
both venous and arterial thrombosis.167 In a study examining
Chinese Han patients, a glycoprotein IIb human platelet an-
tigen 3 a/b polymorphism, speciﬁcally the b allele was linked
to native AVF thrombosis.168 These studies show that changes
in the vessel wall lead to increased thrombogenicity, which is
further compounded by systemic uremia.
Therapeutic strategies and future perspectives
Pharmacological treatments are potential strategies to
improve clinical outcomes of AVF. For example, statin treat-
ment has been previously adopted with the aim to protect
against vascular injury and prolong VA patency. However, in
patients treated with statins, VA survival was not amelio-
rated169 despite the promising results obtained in a murine
model.170 There are potentially several explanations of this
observation including the patients treated with statin were
older, with a higher percentage of diabetics and more were
female. Additionally, the type and amount of statin that was
used was not deﬁned. For example, atorvastatin is more anti-
inﬂammatory than simvastatin, and high-dose statins reduce
VEGFA and MMP expression that has been associated with
HD vascular access failure. In a different study, statin use had
improved outcomes; however, it was not statistically signiﬁ-
cant. In this study as well, statin patients were older and a
higher percentage were diabetic compared with those not on
statins.171 As suggested by Birch and Florescu,172 the anti-
inﬂammatory effects of statins are likely to be insufﬁcient in
AVF remodeling due the underlying ESRD context.
To use new therapeutic strategies, the biological mecha-
nisms responsible for AVF failure must be identiﬁed more
precisely. Despite the important discoveries of the last 20311
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improve our knowledge, it is important to study dynamics of
IH formation in robust animal models. In the patients, new
noninvasive imaging modalities may help to investigate the
dynamic response of the vessel wall after AVF creation. An
additional important aspect of this research is the possibility
to study individual patient responses and to relate them with
pathological conditions and genetic factors. This may allow
clinicians to identify and treat patients at an increased risk of
AVF failure.
Because of the previously discussed role of hemodynamic
factors in development of IH, another strategy we can employ
to improve AVF outcomes is computer-assisted surgical
planning. This software can be used to optimize AVF geom-
etry and reduce blood velocity oscillations, ﬂow, and shear
stress instability.34,173 In addition, we also suggest that
patient-speciﬁc identiﬁcation of AVFs exposed to important
ﬂow oscillations may allow clinicians to identify patients at
increased risk of AVF failure and follow them more closely.
These evaluations could improve AVF maturation and long-
term patency rates.
CONCLUSIONS
AVF complications are the main cause of hospitalization of
dialysis patients with very high social and economical costs. IH
is the principal cause of arteriovenous ﬁstula failure. Currently
available strategies to minimize IH growth and consequent
AVF failure are largely ineffective. Mechanical and pharma-
cological treatments of AVF stenosis present high rates of
restenosis and failure.3,174 There has been a great deal of effort
made to understand the basis of this failure with the aim to
correct it. These studies have revealed several major inter-
twined pathways such as inﬂammation, uremia, hypoxia, and
shear stress leading to IH and propagating thrombosis. How-
ever, the precise mechanisms involved and their interplay are
not completely understood at the moment and the ongoing
research may improve this knowledge in the near future.
Future work will allow for development of surgical strategies,
interventions, and medical management to signiﬁcantly
improve the clinical outcomes of these life-saving procedures.
Because of the importance of hemodynamic factors on
AVF outcome, we suggest that computer-assisted surgical
planning could allow optimizing AVF geometry with the aim
to reduce blood velocity oscillations and ﬂow instability.34,173
In addition, identiﬁcation of AVF exposed to important ﬂow
oscillations may allow us to more intensively follow AVF with
high risk of failure. These evaluations could improve AVF
maturation and long-term patency, limiting uncontrolled IH
growth.
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